Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.53% is 117% above its 5-year average of 41.18%, near the high end of its 5-year range (-2288.34%–98.39%).
93.36% above its 12-month average of 46.30%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -77.97%.
GROSS MARGIN
89.53%
GROSS MARGIN AVG TTM
46.30%
GROSS MARGIN AVG 3Y
50.43%
GROSS MARGIN AVG 5Y
41.18%
GROSS MARGIN AVG 10Y
-131.01%
GROSS MARGIN AVG 15Y
-165.60%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+93.36%
CURRENT VS 3Y AVG
+77.52%
CURRENT VS 5Y AVG
+117.40%
CURRENT VS 10Y AVG
+168.34%
CURRENT VS 15Y AVG
+154.06%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 811 covered companies
CURRENT VS SECTOR MEDIAN
+122.05%
vs the sector median at left
Market Cap
$1.53B
Gross Margin
51.26%
TTM Avg
45.83%
3Y Avg
28.18%
5Y Avg
37.38%
Market Cap
$1.53B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
66.67%
Market Cap
$1.54B
Gross Margin
97.47%
TTM Avg
96.23%
3Y Avg
48.12%
5Y Avg
65.41%
Market Cap
$1.49B
Gross Margin
57.87%
TTM Avg
56.73%
3Y Avg
61.85%
5Y Avg
-49.66%
Market Cap
$1.49B
Gross Margin
33.71%
TTM Avg
32.28%
3Y Avg
31.46%
5Y Avg
31.45%
Market Cap
$1.46B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| uniQure N.V. (QURE) | $1.52B | 89.53% | 46.30% | 50.43% | 41.18% |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 51.26% | 45.83% | 28.18% | 37.38% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | 100.00% | 100.00% | 100.00% | 66.67% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 97.47% | 96.23% | 48.12% | 65.41% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 57.87% | 56.73% | 61.85% | -49.66% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 33.71% | 32.28% | 31.46% | 31.45% |
| GH Research PLC (GHRS)vs › | $1.46B | 0.00% | 0.00% | 0.00% | 0.00% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | 0.00% | 0.00% | 0.00% | 0.00% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 17.33% | 13.16% | 12.65% | 13.31% |
Gross Margin
89.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -77.97% |
| 2026-03-31 | 93.85% |
| 2025-12-31 | 38.85% |
| 2025-09-30 | 89.25% |
| 2025-06-30 | 87.53% |
| 2025-03-31 | 87.43% |
| 2024-12-31 | 88.14% |
| 2024-09-30 | 55.36% |
| 2024-06-30 | 32.94% |
| 2024-03-31 | -8.73% |
| 2023-12-31 | -32.08% |
| 2023-09-30 | 28.50% |
| 2023-06-30 | 44.18% |
| 2023-03-31 | 54.27% |
| 2022-12-31 | 98.39% |
| 2022-09-30 | 40.58% |
| 2022-06-30 | -67.40% |
| 2022-03-31 | -2288.34% |
| 2021-12-31 | 34.36% |
| 2021-09-30 | -1710.76% |
| 2021-06-30 | 95.00% |
| 2021-03-31 | -7092.95% |
| 2020-12-31 | 7.05% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | -909.22% |
| 2019-09-30 | -2151.82% |
| 2019-06-30 | -876.31% |
| 2019-03-31 | -1707.83% |
| 2018-12-31 | -1039.43% |
| 2018-09-30 | -501.68% |
| 2018-06-30 | -506.33% |
| 2018-03-31 | -390.45% |
| 2017-12-31 | -597.45% |
| 2017-09-30 | -652.35% |
| 2017-06-30 | -221.04% |
| 2017-03-31 | -405.69% |
| 2016-12-31 | 97.18% |
| 2016-09-30 | 98.84% |
| 2016-06-30 | 98.07% |
| 2016-03-31 | 98.05% |
| 2015-12-31 | 95.76% |
| 2015-09-30 | 86.41% |
| 2015-06-30 | -552.64% |
| 2015-03-31 | -805.64% |
| 2014-12-31 | -650.09% |
| 2014-09-30 | -845.33% |
| 2014-06-30 | -671.18% |
| 2014-03-31 | -432.44% |
| 2013-12-31 | 98.06% |
| 2013-09-30 | -144.51% |
| 2013-06-30 | -5.54% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 0.00% |
